Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers
Pinkus Tober-Lau,Tatjana Schwarz,Tatjana Schwarz,Kanika Vanshylla,David Hillus,Henning Gruell,Eicov,Norbert Suttorp,Irmgard Landgraf,Irmgard Landgraf,Kai Kappert,Joachim Seybold,Joachim Seybold,Christian Drosten,Florian Klein,Florian Klein,Florian Kurth,Florian Kurth,Victor M. Corman,Leif E. Sander +19 more
Reads0
Chats0
TLDR
Findings suggest that the established two-dose vaccination regimen elicits less durable immune responses in the elderly compared to young adults, and the current data may support booster vaccinations of the elderly.Abstract:
COVID-19 mRNA vaccine BNT162b2 is highly immunogenic and effective, but recent studies have indicated waning anti-SARS-CoV-2 immune responses over time. Increasing infection rates has led authorities in several countries to initiate booster campaigns for vulnerable populations, including the elderly. However, the durability of vaccine-induced immunity in the elderly is currently unknown. Here, we describe interim results of a prospective cohort study comparing immune responses in a cohort of vaccinated elderly persons to those in healthcare workers (HCW), measured six months after first immunisation with BNT162b2. Anti-SARS-CoV-2 S1-, full Spike- and RBD-IgG seropositivity rates and IgG levels at six months were significantly lower in the elderly compared to HCW. Serum neutralization of Delta VOC measured by pseudovirus neutralisation test was detectable in 43/71 (60.6%, 95%CI: 48.9-71.1) in the elderly cohort compared to 79/83 in the HCW cohort (95.2%, 95%CI: 88.3-98.1) at six months post vaccination. Consistent with the overall lower antibody levels, SARS-CoV-2-S1 T cell reactivity was reduced in the elderly compared to HCW (261.6 mIU/ml, IQR:141.5-828.6 vs 1198.0 mIU/ml, IQR: 593.9-2533.6, p Collectively, these findings suggest that the established two-dose vaccination regimen elicits less durable immune responses in the elderly compared to young adults. Given the recent surge in hospitalisations, even in countries with high vaccination rates such as Israel, the current data may support booster vaccinations of the elderly. Further studies to determine long-term effectiveness of COVID-19 vaccines in high-risk populations and the safety and effectiveness of additional boosters are needed.read more
Citations
More filters
Journal ArticleDOI
Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers.
Jean-Louis Bayart,Jonathan Douxfils,Constant Gillot,Clara David,François Mullier,Marc Elsen,Christine Eucher,Sandrine Van Eeckhoudt,Tatiana Roy,Vincent Gerin,Grégoire Wieërs,Christine Laurent,Mélanie Closset,Jean-Michel Dogné,Julien Favresse +14 more
TL;DR: The antibody decline observed in a population of COVID-19 naïve and CO VID-19 positive individuals having received the two dose regimen of the BNT162b2 vaccine six months after vaccination is reported.
Journal ArticleDOI
Advances in COVID-19 mRNA vaccine development
Enyue Fang,Xiaohui Liu,Miao Li,Zelun Zhang,Lifang Song,Baiyu Zhu,Xiao-hong Wu,Jingjing Liu,Danhua Zhao,Yuhua Li +9 more
TL;DR: In this article , the authors summarized current knowledge on the structural characteristics, antigen design strategies, delivery systems, industrialization potential, quality control, latest clinical trials and real-world data of COVID-19 mRNA vaccines as well as mRNA technology.
Journal ArticleDOI
Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Valérie Gounant,Valérie Gounant,Valentine Marie Ferré,Ghassen Soussi,Ghassen Soussi,Charlotte Charpentier,Héloïse Flament,Nadhira Fidouh,Gilles Collin,Céline Namour,Céline Namour,Sandra Assoun,Sandra Assoun,Alexandra Bizot,Alexandra Bizot,Zohra Brouk,Zohra Brouk,Eric Vicaut,Luis Augusto Teixeira,Diane Descamps,Gérard Zalcman,Gérard Zalcman +21 more
TL;DR: In this paper, a prospective vaccine monitoring study was conducted to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer, where patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARSCoV2) vaccine registration trials, it was still unknown whether they would develop a protective antispike antibody response after vaccination.
Journal ArticleDOI
The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2
TL;DR: Comparative evolutionary approaches are used to estimate the durability of immunity and the likelihood of future infections over time following vaccination by messenger RNA (mRNA) and viral vector COVID-19 vaccines, providing quantitative evidence supporting booster vaccination as a crucial approach toward the curtailment of breakthrough infections and reinfections.
Journal ArticleDOI
Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study
TL;DR: In this article , the authors compared the humoral and cellular immune response in 184 participants after two doses of the BioNTech/Pfizer vaccine (BNT162b2) with a mid-term follow-up after 9 months.
References
More filters
Journal ArticleDOI
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
Noa Dagan,Noam Barda,Noam Barda,Noam Barda,Eldad Kepten,Oren Miron,Oren Miron,Shay Perchik,Mark A. Katz,Mark A. Katz,Mark A. Katz,Miguel A. Hernán,Marc Lipsitch,Ben Y. Reis,Ran D. Balicer,Ran D. Balicer +15 more
TL;DR: This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.
Journal ArticleDOI
Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
Madhumita Shrotri,Annalan M D Navaratnam,Vincent Nguyen,Thomas Byrne,Cyril Geismar,Ellen Fragaszy,Sarah Beale,Wing Lam Erica Fong,Parth Patel,Jana Kovar,Andrew Hayward,Robert W Aldridge +11 more
Journal ArticleDOI
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
David Hillus,Tatjana Schwarz,Pinkus Tober-Lau,Kanika Vanshylla,Hana Hastor,Charlotte Thibeault,Stefanie Jentzsch,Elisa T Helbig,Lena J Lippert,Patricia Tscheak,Patricia Tscheak,Marie Luisa Schmidt,Marie Luisa Schmidt,Johanna Riege,Johanna Riege,André Solarek,Christof von Kalle,Chantip Dang-Heine,Henning Gruell,Piotr Kopankiewicz,Norbert Suttorp,Christian Drosten,Christian Drosten,Harald Bias,Joachim Seybold,Florian Klein,Florian Kurth,Florian Kurth,Victor M. Corman,Victor M. Corman,Leif E. Sander +30 more
TL;DR: In this article, an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19-BNT162b2 vaccination with a 10-12-week vaccine interval was performed.
Posted ContentDOI
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas,Edson D. Moreira,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Fernando P. Polack,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Xia Xu,Satrajit Roychoudhury,Kenneth Koury,Salim Bouguermouh,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Qi Yang,Paul A. Liberator,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,William C. Gruber,Kathrin U. Jansen +31 more
TL;DR: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy study, 44,165 ≥16-year-old participants and 2,264 12-15-year old participants were randomized to receive 2 doses, 21 days apart, of 30 µg BNT162b2 or placebo as mentioned in this paper.
Journal ArticleDOI
Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans.
Kanika Vanshylla,Veronica Di Cristanziano,Franziska Kleipass,Felix Dewald,Philipp Schommers,Lutz Gieselmann,Henning Gruell,Maike Schlotz,Meryem S. Ercanoglu,Ricarda Stumpf,Petra Mayer,Matthias Zehner,Eva Heger,Wibke Johannis,Carola Horn,Isabelle Suárez,Norma Jung,Susanne Salomon,Kirsten Alexandra Eberhardt,Kirsten Alexandra Eberhardt,Birgit Gathof,Gerd Fätkenheuer,Nico Pfeifer,Ralf Eggeling,Max Augustin,Clara Lehmann,Florian Klein +26 more
TL;DR: In this article, the authors evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19 and found that approximately 3% of individuals demonstrated exceptional SARSCoV2 neutralization, with these "elite neutralizers" also possessing SARS CoV-1 cross-neutralizing IgG.
Related Papers (5)
Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
Significant reduction in humoral immunity among healthcare workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA vaccination
David H. Canaday,David H. Canaday,Oladayo A. Oyebanji,Debbie Keresztesy,Mike C. Payne,Dennis Wilk,Lenore Caris,Htin Aung,Kerri St. Denis,Evan C. Lam,Christopher F. Rowley,Sarah Berry,Cheryl M. Cameron,Mark J. Cameron,Brigid Wilson,Alejandro B. Balazs,Christopher L. King,Stefan Gravenstein,Stefan Gravenstein +18 more